Biocept, Inc. (NASDAQ: BIOC) is a commercial-stage molecular diagnostics company that utilizes a proprietary technology platform and a standard blood sample to provide physicians with important prognostic and predictive information to enhance individual treatment of patients with cancer, according to the company’s website (see here: www.Biocept.com). In this SNNLive On-Location, our host spoke with Michael W. Nall, President and CEO of Biocept, Inc. in New York City, NY.
In this video interview, Mr. Nall and our host discuss the following topics:
- Overview of Biocept, Inc.
- Discusses the concept, “Liquid Biopsy”
- Describes the company’s technology
- Comments on collaboration with Insight Genetics
- History of Biocept
- Growth drivers for Biocept
- Average cost of the test
- Outlook for 2015-2016
Since speaking with Mr. Nall, the company has made the following announcements:
For more information about Biocept, Inc., go to: www.Biocept.com
© 2017 Stock News Now
Supported by Superior Web Solutions